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We thank the associate editor and reviewers for taking the time to review our manuscript and for 
their overall positive comments.  Please find below our responses to the individual comments: 
 
Associate Editor: 
1) Please add the interventions section at the abstract. Thanks. 
The ‘Design, Setting and Participants’ section of the abstract has been split to incorporate the 
interventions sections and now reads (lines 45-47): 
 
‘Design, Setting, and Participants: A retrospective analysis was conducted of a second-line phase II 
study in metastatic ccRCC (NCT00942877), evaluating 138 patients with 458 baseline lesions.   
Intervention: The phase II trial assessed VEGF-targeted therapy ± Src inhibition.’ 
 
The words ‘to validate these findings’ have been removed from the abstract conclusion (line 61) to 
keep the word count below 300. 
 
2) The authors used definitions of radiological heterogeneity which were developed in patients 
with CRC liver mets and which were modified accordingly by the authors. Are the cut-offs 
used for 'homogeneous', 'low heterogeneous' and 'high heterogeneous' response arbitrary or 
is there evidence why these were chosen by the authors. Please briefly clarify to make it more 
understandable for our readers. 
The following has been added to the Patients and Methods section (lines 152-155): 
‘The cut-offs were determined using an optimal response model by van Kessel and colleagues.  This 
involved modelling different cut-off values to identify which provided the highest discriminative 
capacity.  Further details are provided in [6].  No further modelling was undertaken for the analysis 
presented in this paper.’ 
 
3) Please add the number of patients at risk at each time point with KM-curves. Please also use 
12-mo intervals to make it easier to see yearly changes. 
Figures 2 and 3 have been updated as suggested. 
 
4) Please briefly explain the development of the multivariate model. Which parameters from 
the univariate model were included? Which parameters were used for the univariate 
analyses? 
 
The Statistical Analysis section of Patients and Methods (lines 159-165) has been updated to clarify 
these points and now reads:   
*Revision notes
‘Uni- and multivariate analyses were undertaken using Cox regression to calculate Hazard Ratios 
(HR).  The univariate parameters were chosen on the basis of being known prognostic variables from 
previous studies (gender, Eastern Cooperative Oncology Group [ECOG] performance status, 
Memorial Sloan Kettering Cancer Center [MSKCC] risk group, nephrectomy status) or because they 
may be confounding factors to radiological heterogeneity (number of target lesions, sum of lesion 
diameters) [2, 7, 8].  All univariate parameters were included in the multivariate analysis.’  
 
Reviewer 1: 
We thank the reviewer for their kind comments. 
 
Reviewer 2: 
We thank the reviewer for their kind comments. 
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ABSTRACT 40 
Background: Response Evaluation Criteria in Solid Tumours (RECIST) is widely used to assess tumour 41 
response but is limited by not considering disease site or radiological heterogeneity.   42 
Objective: To determine if radiological heterogeneity or disease site have prognostic significance in 43 
patients with metastatic clear cell renal cell carcinoma (ccRCC). 44 
Design, Setting, and Participants: A retrospective analysis was conducted of a second-line phase II 45 
study in metastatic ccRCC (NCT00942877), evaluating 138 patients with 458 baseline lesions.   46 
Intervention: The phase II trial assessed VEGF-targeted therapy ± Src inhibition.  47 
Outcome Measurements and Statistical Analysis: Radiological heterogeneity at week 8 was 48 
assessed within individual patients with ≥2 lesions to predict overall survival (OS) using Kaplan-Meier 49 
method and Cox regression.  We defined a high heterogeneous response as occurring when ≥1 50 
lesion underwent a ≥10% reduction and ≥1 lesion underwent a ≥10% increase in size.  Disease 51 
progression was defined by RECIST 1.1 criteria. 52 
Results and Limitation: In patients with a complete/partial response or stable disease by RECIST 1.1 53 
and ≥2 lesions at week 8, those with a high heterogeneous response had a shorter OS compared to 54 
those with a homogeneous response (hazard ratio [HR] 2.01 (95% confidence interval [CI]: 1.39-2.92; 55 
P<0.001).  Response by disease site at week 8 did not affect OS.  At disease progression, ≥1 new 56 
lesion was associated with worse survival compared to >20% increase in sum of target lesion 57 
diameters only (HR 2.12; 95% CI: 1.43-3.14; P<0.001).  Limitations include retrospective study design. 58 
Conclusions: Radiological heterogeneity and the development of new lesions may predict survival in 59 
metastatic ccRCC.  Further prospective studies are required. 60 
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Patient summary: We looked at individual metastases in patients with kidney cancer and showed 61 
that a variable response to treatment and the appearance of new metastases may be associated 62 
with worse survival.  Further studies are required to confirm these findings. 63 
 64 
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INTRODUCTION  100 
Inhibition of vascular endothelial growth factor (VEGF) signalling, usually by means of small-molecule 101 
tyrosine kinase inhibitors (TKIs), is the current mainstay of metastatic clear-cell renal cell carcinoma 102 
(ccRCC) therapy in both the first and second-line settings [1].  However, there is a wide variation in 103 
treatment responses by patients.  Several prognostic scoring systems have been developed to 104 
identify poor and favourable risk patients [2, 3].  These are determined at baseline and are based 105 
around a combination of time to treatment, performance status and blood parameters [2, 3].  106 
Response Evaluation Criteria in Solid Tumours (RECIST) response rates and disease progression have 107 
been used as surrogate markers of activity in clinical trials [4].  However, RECIST is limited as it 108 
overlooks details of dynamic changes by amalgamating total tumour burden into a single numerical 109 
entity.  Confidence in RECIST as accurate surrogate marker of outcome is also questionable, partly 110 
due to variable responses within individual patients, also known as intra-patient heterogeneity.  For 111 
these reasons, clinicians often continue treatment past disease progression.  Therefore, more 112 
accurate tools for predicting outcome are required.  We hypothesised that following individual 113 
lesion responses would better characterise clinical benefit.  We therefore examined individual 114 
lesions in patients with metastatic ccRCC participating in a VEGF-targeted therapy clinical trial to 115 
address this. 116 
 117 
PATIENTS AND METHODS 118 
Study population 119 
Prospectively collected data from the double-blind, randomised, phase II COSAK trial 120 
(ClinicalTrials.gov NCT00942877) were used in this retrospective post hoc analysis.  One hundred and 121 
thirty-eight patients with metastatic ccRCC who had progressed after at least one line of VEGF 122 
targeted therapy were randomised to either cediranib (a VEGF TKI) alone (N=69) or in combination 123 
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with the Src inhibitor, saracatinib (N=69).  Exclusion criteria included untreated brain metastases, 124 
uncontrolled hypertension and concurrent malignancies.  The two arms were well-matched for 125 
patient characteristics.  No significant difference was seen in progression-free survival (PFS) or 126 
overall survival (OS), published elsewhere [5].  The data from the two treatment arms were 127 
therefore combined for this analysis.   128 
 129 
Imaging and image analysis 130 
Computed tomography (CT) scans were undertaken every eight weeks using standard protocols and 131 
patient response assessed by RECIST 1.1 [4].  Staff were blinded to the outcome data, but no central 132 
review occurred.  Baseline, week 8 and disease progression were the time points examined.  133 
Individual lesion responses (percentage change from baseline) for each patient were also 134 
determined at week 8.  RECIST 1.1 criteria were used to categorise each lesion response.   135 
 136 
Radiological heterogeneity 137 
Radiological heterogeneity (RH) was assessed at week 8 in patients with ≥2 lesions using criteria 138 
developed by van Kessel and colleagues in patients with colorectal liver metastases (Suppl. Fig. 1, 139 
[6]).  They used the terms ‘homogeneous’, ‘mixed’ and ‘true mixed’ response, but ‘true’ implies a 140 
validated comparison with a gold standard.  We therefore have used the terms ‘homogeneous’, ‘low 141 
heterogeneous’ and ‘high heterogeneous’ response instead.  142 
Briefly, the percentage change in each lesion was determined and the maximum difference 143 
calculated.  A homogeneous response indicated that all the lesions for a patient had changed in the 144 
same direction with <30% difference between highest and lowest change.   A low heterogeneous 145 
response indicated that all lesions changed in same direction, but that there was a ≥30% difference 146 
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between the highest and lowest.  For the homogeneous and low heterogeneous response 147 
categories, small changes (-10% to +10%) could be re-assigned to count as a change in the same 148 
direction.  A high heterogeneous response indicated that at least one lesion underwent a ≥10% 149 
reduction and at least one other lesion underwent a ≥10% increase.  The cut-offs were determined 150 
using an optimal response model by van Kessel and colleagues.  This involved modelling different 151 
cut-off values to identify which provided the highest discriminative capacity.  Further details are 152 
provided in [6].  No further modelling was undertaken for the analysis presented in this paper. 153 
 154 
Statistical analysis 155 
The primary outcome for this study was OS.  Kaplan-Meier method was used to assess OS and 156 
groups compared using the log-rank test.  Uni- and multivariate analyses were undertaken using Cox 157 
regression to calculate Hazard Ratios (HR).  The univariate parameters were chosen as known 158 
prognostic variables from previous studies (gender, Eastern Cooperative Oncology Group [ECOG] 159 
performance status, Memorial Sloan Kettering Cancer Center [MSKCC] risk group, nephrectomy 160 
status) or because they may be confounding factors to RH (number of target lesions, sum of lesion 161 
diameters) [2, 7, 8].  All univariate parameters were included in the multivariate analysis.  Pearson’s 162 
Chi-Square test was used to assess differences in RH between two groups.  All statistical analyses 163 
were conducted using Statistical Package for the Social Sciences (SPSS, version 23). A P value of 164 
<0.05 was considered significant. 165 
 166 
RESULTS 167 
Patients 168 
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All 138 patients from the COSAK trial were evaluated (Table 1).  Ninety-six percent of patients had 169 
received only one previous VEGF-targeted therapy whereas the remainder had received two.  170 
Median PFS and OS for the whole group were 4.1 months (95% confidence interval (CI): 3.1-5.1 171 
months) and 12.0 months (95% CI: 8.5-15.6 months), respectively.  No significant difference 172 
between the treatment arms was observed with regards to both baseline characteristics and 173 
treatment response (P>0.05).  Therefore, the data for the two treatment arms were merged for this 174 
analysis.  175 
 176 
Baseline site of disease 177 
At baseline, 458 individual lesions from 138 patients were available for analysis.  The median 178 
number of lesions per patient was 3 (range 1-5).  A breakdown of the lesion sites was as follows: 179 
lymph nodes 138 (30%); lung 112 (24%); liver 42 (9%); bone 27 (6%); other 139 (30%).  Twenty-seven 180 
patients had ≥ 1 liver metastasis (20%) and 18 (13%) had ≥ 1 bone metastasis.  Two patients (1.4%) 181 
had both a liver and bone metastasis.  The presence of a liver or bone metastasis was not predictive 182 
of PFS (HR 0.95; 95% CI: 0.66-1.38; P=0.80) or OS (HR 1.34; 95% CI: 0.91-1.97; P=0.14). 183 
 184 
First follow-up CT scan (week 8) 185 
The first follow-up CT scan occurred at week 8.  One hundred and thirteen patients (82% of baseline) 186 
had week 8 data for analysis encompassing 369 of the baseline lesions (81%; lymph nodes 103 [28% 187 
of the 369], Lung 93 [25%], liver 30 [8%], bone 26 [7%], other 117 [32%]).  Reasons for the reduced 188 
patient numbers at week 8 included death and drug toxicity.   189 
 190 
Individual lesion responses at week 8 191 
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Assessment of the individual lesion responses at week 8 by RECIST criteria showed one complete 192 
response (0.3%), 49 partial responses (13%), 276 (75%) were classified as stable and 43 (12%) lesions 193 
progressed (Suppl. Table 1A).  Lesion site responses of CR/PR (combined as only one lesion had a 194 
CR), SD or PD were not prognostic for OS (Suppl. Table 1B).   195 
 196 
Overall patient responses at week 8 197 
When overall patient responses were analysed by RECIST at week 8, no patients had a CR, 8 (7.1%) 198 
had a PR, 80 (70.8%) had SD and 25 (22.1%) had PD.  As expected, PD at week 8 was associated with 199 
worse OS with a median of 3.9 months (95% CI: 1.0-6.8) compared to 12.1 months (95% CI: 9.7-14.5; 200 
HR 1.61; 95% CI: 1.07-2.43; P=0.02) for patients with a PR and 13.9 months (95% CI: 12.2-15.6; HR 201 
3.21; 95% CI: 2.10-4.93; P<0.001) for patients with SD.  No statistical difference was seen between 202 
the PR and SD groups (HR 0.82; 95% CI: 0.37-1.79; P=0.61). 203 
 204 
Radiological heterogeneity at week 8 205 
Given that no difference in outcome was seen between the RECIST-defined PR and SD groups at 206 
week 8, we examined whether OS in this subpopulation could be further characterised by RH.  Of the 207 
113 patients with individual lesion data available at week 8, 104 (75% of the initial 138 patients) had 208 
>1 lesion and therefore could be assessed for heterogeneity.  Of these 104 patients, 81 (59% of the 209 
initial 138 patients), had PR (N=7) or SD (N=74) by RECIST at week 8 and were included in the 210 
heterogeneity analysis.  The remaining 23 patients had PD by RECIST criteria and were not included.   211 
Figure 1 demonstrates the frequency of different lesion responses by RECIST category for PR and SD 212 
patients combined.  Radiological heterogeneity was commonly seen, with 34 patients (42%) having 213 
≥2 RECIST categories amongst their lesion responses at week 8.  However, heterogeneity by number 214 
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of RECIST categories (1 versus ≥2) was not associated with improved OS (HR 1.40; 95% CI: 0.84-2.32; 215 
P=0.19).  216 
Radiological heterogeneity was assessed using criteria developed for colorectal liver metastases in 217 
the RECIST-defined PR and SD populations (Suppl. Fig. 1; [6]).  Forty nine patients (60%) had a 218 
homogeneous response, 20 (25%) had a low heterogeneous response and 12 (15%) had a high 219 
heterogeneous response by RH criteria.  For OS from week 8, the times were 16.9 months (Fig. 2; 220 
95% CI: 11.1-22.7), 12.8 months (95% CI: 11.3-14.3) and 7.3 months (95% CI: 5.4-9.2) for the 221 
homogeneous, low heterogeneous and high heterogeneous response categories, respectively.  222 
Hazard ratios were: Homogeneous vs low heterogeneous 1.41 (95% CI: 0.78-2.55; P=0.26); 223 
Homogeneous vs high heterogeneous 2.01 (95% CI: 1.39-2.92; P<0.001); low heterogeneous vs high 224 
heterogeneous 2.58 (95% CI: 1.12-5.91; P=0.02).   225 
We hypothesised that patients with smaller, more numerous lesions may demonstrate increased RH 226 
and therefore confound results.  Of the 81 patients in the RH analysis, 28 (35%) had two target 227 
lesions and 53 (65%) had ≥3 lesions.  The number of target lesions (2 vs ≥3) was not prognostic for 228 
OS (HR 0.66; 95% CI: 0.39-1.12; P=0.13).  The median sum of target lesion diameters at week 8 was 229 
92 mm (range 20-334).  A sum below the median was associated with improved OS (HR 0.45; 95% CI: 230 
0.27-0.74; P=0.002), but RH was not significantly different between the two groups (Suppl. Fig. 2; 231 
P=0.17).  However, in a multivariate Cox regression including RH, sum of lesion diameters, number of 232 
lesions alongside the other variables, only RH, sum of lesion diameters and MSKCC score were 233 
independent prognostic factors for OS (Table 2).   234 
Radiological heterogeneity was not prognostic for OS in patients with PD at week 8, although 235 
numbers were small (HR 0.76, 95% CI: 0.31-1.83; P=0.54; N=23). 236 
 237 
New lesions at disease progression predict worse survival 238 
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One hundred and twenty one patients (88% of the initial 138) had data at disease progression.  Of 239 
these, 64 (53%) had no new sites of disease and 57 (47%) had ≥1 new site.  Lung was the commonest 240 
site of for a new lesion (23 patients, 41%) with liver and ‘other’ being the next commonest sites (16 241 
patients each, 29%).  This was followed by bone (13 patients, 21%), lymph node (8 patients, 14%) 242 
and brain (2 patients, 4%).  The new site was unknown for one patient.  Median survival was 243 
significantly shorter in patients with ≥1 new site of disease compared to none at disease progression 244 
(Fig. 3; 3.7 months [95% CI: 2.1-5.2] versus 9.9 months [95% CI: 7.5-12.2]; HR 2.12; 95% CI: 1.43-3.14; 245 
P<0.001).  In patients with ≥1 new disease site, 32 patients (56%) had a <20% increase in the sum of 246 
lesion diameters at disease progression, 21% had ≥20% increase and 23% had missing data.  No 247 
significant difference in survival was seen between the groups suggesting new sites rather than 248 
general progression in all sites was associated with poor outcome (HR 0.87; 95% CI: 0.42-1.79; 249 
P=0.66).  The site of the new lesion was not predictive for survival (Suppl. Table 2). 250 
 251 
DISCUSSION 252 
This study examined radiological prognostic factors at baseline, first follow-up scan (week 8) and 253 
disease progression in metastatic ccRCC patients receiving second-line VEGF-targeted therapy.   254 
Whilst patients with PD at first follow-up had a worse survival, no significant difference in survival 255 
was seen between patients with PR or SD when using RECIST 1.1 criteria.  Therefore, alternative 256 
radiological prognostic markers were sought for these patients to predict prognosis and thus aid 257 
treatment decisions.  Forty percent of patients with non-progressive disease at week 8 258 
demonstrated RH, with increased RH associated with worse survival.  Intratumoural and inter-259 
metastasis heterogeneity has been shown to exist at a molecular level in RCC where clonal evolution 260 
is thought to play a role [9-11].  Similarly, RH has been shown to exist in metastatic ccRCC patients 261 
treated with first-line VEGF-targeted therapies at a similar frequency to that seen in this study and is 262 
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likely to represent different clones [12].  However, no outcome data were analysed.  Radiological 263 
heterogeneity has also been shown in patients with colorectal liver metastases where increased RH 264 
was correlated to a worse OS [6].  We have described a method to assess RH that can be used in the 265 
clinic and, in our dataset, had prognostic significance for patients with metastatic ccRCC at their first 266 
follow-up scan thereby providing a potential alternative to RECIST for assessing treatment response.  267 
This may be beneficial to patients as ineffective treatments can be changed at an earlier timepoint.   268 
Radiological heterogeneity was found to be independent of potential confounders, number of target 269 
lesions and sum of lesion diameters, but further validation is required.  Future studies may also look 270 
at the correlation between RH and tumour factors including Fuhrman grade and Von-Hippel-Lindau 271 
mutational status.  272 
The development of ≥1 new lesion, rather than the growth of existing lesions, at disease progression 273 
was associated with a worse OS.  This has previously been described for metastatic RCC patients 274 
treated with everolimus [13].  Similar effects have been shown in metastatic breast, colorectal and 275 
lung cancer [14, 15].  RECIST does not distinguish between the two types of disease progression, 276 
thereby reflecting a further limitation of its use.  The development of new sites suggests increased 277 
clinical significance and may help decision making in terms of switching therapy. 278 
Baseline site of disease was not a prognostic factor for OS in this study.  In addition, treatment 279 
response at week 8 by disease site was not prognostic for survival.  This is in contrast to previous 280 
studies which have shown that bone and liver metastases are adverse independent prognostic 281 
factors for OS in metastatic RCC [16-18].  This correlates with findings from patients treated with 282 
cytokines where liver and bone metastases have been included as adverse factors in a prognostic 283 
model [19].  It is unclear why bone and liver metastases were not prognostic in this study, although 284 
low N numbers may be one explanation. 285 
There are several limitations of this study.  This was a retrospective study that was not powered for 286 
the groups analysed and therefore requires validation before definitive conclusions can be reached, 287 
14 
 
 
 
ideally with prospective studies.  The N numbers in this study were small, making it difficult to reject 288 
to the null hypothesis.  Nonetheless, even with this restriction, we did manage to show significant 289 
results.  Cediranib is not licensed for use in RCC, having not been developed further due largely to 290 
the competitive landscape in metastatic RCC.  Its efficacy appears to be in line with other VEGF-291 
targeted therapies tested in the ≥2nd line setting, but further work is required to see if the 292 
conclusions from this paper are applicable to other VEGF-targeted therapies in both the first- and 293 
second-line settings [5, 20].   294 
 295 
CONCLUSIONS 296 
In conclusion, we have shown that radiological heterogeneity may have prognostic value at the first 297 
follow-up scan and may help guide decisions about whether to change treatments.  Similarly, the 298 
development of new lesions at disease progression is associated with a worse survival than solely an 299 
increase in the size of existing lesions.  Further prospective validation is required to confirm these 300 
findings. 301 
 302 
PATIENT SUMMARY 303 
We looked at individual metastases in patients with kidney cancer and showed that a variable 304 
response to treatment and the appearance of new metastases may be associated with worse 305 
survival.  Further studies are required to confirm these findings. 306 
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TABLE LEGENDS 407 
Table 1: Patients’ characteristics at baseline.  VEGF, vascular endothelial growth factor.  MSKCC, 408 
Memorial Sloan Kettering Cancer Center. 409 
 410 
Table 2: Multivariate Cox regression analysis of variables affecting overall survival at week 8.  411 
ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan Kettering Cancer Center. 412 
 413 
FIGURE LEGENDS 414 
Figure 1: Frequencies of individual lesion response categories by RECIST 1.1 at week 8 in patients 415 
with non-progressive disease.  Individual lesion responses were assessed according to RECIST 1.1 416 
criteria in patients who had an overall response of either PR or SD at week 8 (no CR by patient).  417 
Note, only one lesion had a CR and therefore was combined with the PR group.  The types of RECIST 418 
category demonstrated by the lesions within a patient were assessed and the number of patient 419 
with those categories determined.  CR, complete response; PR, partial response; SD, stable disease; 420 
PD, progressive disease. 421 
 422 
Figure 2: Radiological heterogeneity in patients with a partial response or stable disease at week 8 423 
is associated with overall survival.  In patients with a partial response or stable disease at week 8, 424 
radiological heterogeneity (homogeneous response, low heterogeneous response, high 425 
heterogeneous response) is prognostic for overall survival: 16.9 months (95% CI: 11.1-22.7), 12.8 426 
months (95% CI: 11.3-14.3) and 7.3 months (95% CI: 5.4-9.2) for the homogeneous response, low 427 
heterogeneous response and high heterogeneous response categories, respectively.  Hazard ratios 428 
were as follows: Homogeneous vs Low heterogeneous 1.41 (95% CI: 0.78-2.55; P=0.26); 429 
19 
 
 
 
Homogeneous vs High heterogeneous 2.01 (95% CI: 1.39-2.92; P<0.001); Low heterogeneous vs High 430 
heterogeneous 2.58 (95% CI: 1.12-5.91; P=0.02).    431 
 432 
Figure 3: One or more new lesion at disease progression is associated with worse overall survival.  433 
%).  Median survival was significantly shorter in patients with ≥1 new site of disease compared to 434 
none at disease progression (3.7 months [95% CI: 2.1-5.2] versus 9.9 months [95% CI: 7.5-12.2]; HR 435 
2.12; 95% CI: 1.43-3.14; P<0.001).   436 
 437 
SUPPLEMENTARY TABLE/FIGURE LEGENDS 438 
Supplementary Table 1: Lesion response by site at first follow-up scan (week 8).  Individual lesion 439 
responses were assessed by RECIST 1.1 criteria (A).  Only one lesion had a CR at week 8 and was 440 
therefore combined with the PR category.  Hazard ratios for overall survival (OS) were analysed by 441 
site and RECIST 1.1 response in individual lesions (B).  None were predictive for OS (P>0.05).  CR, 442 
complete response; PR, partial response; SD, stable disease; PD, progressive disease; N/A, not 443 
applicable due to low N numbers; ( ) indicate 95% confidence interval. 444 
 445 
Supplementary Table 2: Site of new lesion at disease progression does not predict survival.  Hazard 446 
ratios for the site of the new lesion at disease progression compared to all other sites.  N/A, not 447 
applicable due to low N numbers. 448 
 449 
Supplementary Figure 1: Methods used to assess radiological response heterogeneity.  Radiological 450 
response heterogeneity was assessed at week 8 in patients with ≥2 lesions.  The percentage change 451 
in each lesion was determined and the maximum difference calculated.  A homogeneous response 452 
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indicated that all the lesions for a patient had changed in the same direction with <30% difference 453 
between highest and lowest change.   A low heterogeneous response indicated that all lesions 454 
changed in same direction, but that there was a ≥30% difference between the highest and lowest.  455 
For the homogeneous and low heterogeneous response categories, small changes (-10% to +10%) 456 
could be re-assigned to count as a change in the same direction.  A high heterogeneous response 457 
indicated that at least one lesion underwent a ≤10% reduction and at least one other lesion 458 
underwent a ≥10% increase [6].   459 
 460 
Supplementary Figure 2: Radiological heterogeneity by sum of lesion diameters in patients with PR 461 
or SD at week 8.  Percentage of patients with a sum of lesion diameters below (blue bars) or above 462 
the median size (orange bars) at week 8 which fall into the homogeneous, low heterogeneous or 463 
high heterogeneous radiological response categories.  The difference between the two groups was 464 
not significant by Pearson’s Chi-Square test (P=0.17).   465 
 466 
Figure 1
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Figure 2
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Figure 3
Click here to download high resolution image
Gender Male 108 (78%) 
Previous immune therapy Yes 29 (21%) 
Performance status 0 37 (27%) 
 1 83 (60%) 
 >1 18 (13%) 
MSKCC risk group Low 19 (14%) 
 Intermediate 99 (72%) 
 High 20 (14%) 
Nephrectomy Yes 111 (80%) 
Site of disease (by patient) Lymph nodes 65 (47%) 
 Lung 92 (67%) 
 Liver 13 (9%) 
 Bone 20 (14%) 
1st line VEGF-targeted therapy Sunitinib 109 (81%) 
 Pazopanib 17 (12%) 
 Sorafenib 4 (3%) 
 Bevacizumab 4 (3%) 
Best response to 1st VEGF- Complete response 2 (1%) 
targeted therapy Partial response 25 (18%) 
 Stable disease 53 (38%) 
 Progressive disease 49 (35%) 
 
Table 1
Variable Hazard ratio (95% CI) P value 
   
Number of target lesions 1.53 (0.75-3.12) 0.83 
Prior nephrectomy 1.51 (0.74-3.08) 0.25 
ECOG performance status 1.37 (0.81-2.32) 0.24 
Gender 
Radiological heterogeneity 
Sum of lesion diameters 
MSKCC score 
0.74 (0.40-1.36) 
1.76 (1.22-2.54) 
0.51 (0.30-0.85) 
1.83 (1.03-3.23) 
0.33 
0.003 
0.01 
0.04 
 
 
Table 2
Supplementary Figure 1
Click here to download high resolution image
Supplementary Figure 2
Click here to download high resolution image
A: Individual lesion responses by RECIST 1.1 criteria at week 8 
 
 
B: Hazard ratios for overall survival by lesion site at week 8 
 
Site Total No. CR/PR SD PD 
Total 369 50 (14%) 276 (75%) 43 (12%) 
Lymph node 103 (28%) 17 (16%) 74 (72%) 12 (12%) 
Lung 93 (25%) 15 (16%) 67 (72%) 11 (12%) 
Liver 30 (8%) 0 (0%) 21 (70%) 9 (30%) 
Bone 26 (7%) 1 (4%) 23 (88%) 2 (8%) 
Other 117 (32%) 17 (14%) 91 (78%) 9 (8%) 
Baseline site CR/PR SD PD 
Lymph node  1.23 (0.66-2.46) 1.11 (0.83-1.48) 1.10 (0.56-2.17) 
Lung  0.72 (0.35-1.50) 0.90 (0.66-1.21) 0.78 (0.38-1.60) 
Liver  N/A 1.14 (0.69-1.90) 1.22 (0.57-2.61) 
Bone  N/A 1.17 (0.76-1.82) N/A 
Other  1.24 (0.64-2.40) 0.91 (0.69-1.19) 0.84 (0.37-1.91) 
Supplementary Table 1
Site of new lesion Hazard ratio (95% CI) P value 
   
Lung 1.65 (0.94-2.91) 0.08 
Liver 1.33 (0.73-2.42) 0.35 
Other 1.14 (0.61-2.11) 0.69 
Bone 
Lymph node 
Brain 
 
1.34 (0.70-2.58) 
0.71 (0.32-1.58) 
N/A 
 
0.38 
0.40 
N/A 
 
 
 
Supplementary Table 2
Assessment by RECIST is widely used to assess treatment response in metastatic RCC patients, but is 
limited in scope.  We show radiological heterogeneity within a patient is important.  Progressive 
disease with ≥1 new disease sites is indicative of worse survival. 
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